Greenwich LifeSciences Reports ~80% Reduction in Breast Cancer Recurrence in Phase III FLAMINGO-01 Non-HLA-A*02 Arm

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO...

December 16, 2025 | Tuesday | News
InnoCare’s Orelabrutinib Meets Primary Endpoint in Phase IIb SLE Study, Advances to Phase III

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced th...

December 15, 2025 | Monday | News
J&J’s AKEEGA Wins FDA Approval After Cutting Progression Risk by More Than Half in BRCA2-Mutated mCSPC

Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (n...

December 15, 2025 | Monday | News
Savara Secures Key European Patent for MOLBREEVI as It Prepares Global Regulatory Filings

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the EPO notified the...

December 12, 2025 | Friday | News
China Approves InnoCare’s Breakthrough TRK Inhibitor Zurletrectinib for Adult and Adolescent Solid Tumors

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced that its next-generation TRK inhibitor, zurletrectinib (ICP-72...

December 12, 2025 | Friday | News
Igyxos Biotherapeutics Reports Positive Phase 1 Results for First-in-Class Infertility Antibody IGX12

Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced the s...

December 11, 2025 | Thursday | News
Mindpeak Secures First Patent for Breakthrough AI Method in Digital Pathology

Mindpeak, a global pioneer in AI-powered pathology solutions, is  thrilled to announce that it has been granted its first patent, covering a groundb...

December 11, 2025 | Thursday | News
Gilead Foundation Commits More Than $3 Million To Support Metastatic Breast Cancer Care

Gilead Foundation announced a commitment of more than $3 million in new grants to help address critical gaps in education, care delivery and support serv...

December 10, 2025 | Wednesday | News
Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Tumor Profiling Program to China

Pillar Biosciences and AstraZeneca announced an expansion of their existing laboratory access program for NGS-based kitted liquid biopsy tumor profi...

December 09, 2025 | Tuesday | News
GE HealthCare and Mayo Clinic Launch GEMINI-RT to Advance Personalized Radiation Therapy

GE HealthCare and Mayo Clinic launch GEMINI-RT, a strategic initiative to personalize radiation therapy by integrating imaging, AI, and patient monit...

December 05, 2025 | Friday | News
Bayer Initiates Phase IIa ASSESS Trial of Investigational Antibody BAY 3401016 for Alport Syndrome

BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involve...

December 05, 2025 | Friday | News
Taiho Oncology Europe Announces UK Launch of Lytgobi (Futibatinib) for Eligible Patients With Locally Advanced or Metastatic Cholangiocarcinoma

Taiho Oncology Europe GmbH announced the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibi...

December 04, 2025 | Thursday | News
VNA-318 Demonstrates Strong Target Engagement and Safety in First-in-Human Trial

VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation and improve mitochondrial function First-i...

December 03, 2025 | Wednesday | News
Imugene and JW Therapeutics Collaborate on Innovative CF33-CD19 and CAR-T Therapy for Solid Tumors

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlyt...

December 01, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close